

Special Issue

Gynecological Malignancies: From Molecular Mechanisms to Precision and Regenerative Medicine

Message from the Guest Editors

Gynecological malignancies remain a major cause of cancer-related morbidity and mortality among women worldwide. This Special Issue aims to provide a multidisciplinary platform for high-quality original research and comprehensive reviews addressing the molecular mechanisms underlying gynecological cancers and their clinical translation. Topics of interest include tumor biology, genomic and epigenetic alterations, biomarkers for diagnosis, prognosis and treatment response, targeted therapies, immunotherapy, minimally invasive surgical innovations, lymphatic mapping, cancer survivorship, regenerative medicine, cell-based therapies, tissue engineering, translational research, patient-derived models, precision disease modeling, and advanced preclinical platforms for therapeutic development. Studies integrating emerging technologies, artificial intelligence, multi-omics, and personalized therapeutic strategies are also encouraged. By bringing together basic, translational, and clinical research, ultimately contributing to improved prevention, diagnosis, treatment, and quality of life for patients with gynecological malignancies.

Guest Editors

Dr. Ibon Jaunarena

1. Department of Obstetrics and Gynecology, Donostia University Hospital, San Sebastián, Spain
2. Biogipuzkoa Health Research Institute, San Sebastián, Spain
3. Department of Medical-Surgical Specialties, University of the Basque Country (UPV/EHU), Leioa, Spain

Dr. Héctor Lafuente

BioAraba Health Research Institute, Donostia-San Sebastian, Spain

Deadline for manuscript submissions

31 March 2027



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/287527

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).